Provention bio announces $60 million private placement

Red bank, n.j. , july 7, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has entered into a securities purchase agreement with institutional investors for the private placement of approximately $60 million of shares of its common stock and warrants to acquire 13,318,535 additional shares of its common stock (the "warrants") (collectively, the "securities").
PRVB Ratings Summary
PRVB Quant Ranking